Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review

Woo, Young Sup; Lim, Hyun Kook; Wang, Sheng‐Min; Bahk, Won‐Myong

doi:10.3390/ijms21186969

Cited by 22 publications

(19 citation statements)

References 232 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors), might also improve cerebral microvascular function and have neuroprotective effects through non-lipid and non-glucose pathways. Small trials and observational studies (119)(120)(121)(122) suggest that these drugs may lower depressive symptoms. In addition, several trials are being done to evaluate the effect of statins (e.g.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives

Empana

Boutouyrie

Lemogne

et al. 2021

Biological Psychiatry

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Pharmacological Interventionsmentioning

confidence: 99%

Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives

Empana

Boutouyrie

Lemogne

et al. 2021

Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…Among them, serotonin drug Agomelatine significantly reduced the scores of depression and anxiety at the end of the treatment of depression caused by type 2 diabetic comorbidities ( Norman and Olver, 2019 ). Anti-hyperglycemic such as Insulin and Anti-Hyperglycemic Agents, which agents have demonstrated antidepressant properties in clinical trials, probably due to their action on brain targets based on the shared pathophysiology of depression and T2DM ( Woo et al, 2020 ). In addition, there are tricyclic antidepressants, monoamine oxidase inhibitor, atypical antidepressants, and some traditional Chinese medicine antidepressants ( Zhang X. et al, 2017 ).…”

Section: Clinical Therapeutic Intervention Strategymentioning

confidence: 99%

Update on the Relationship Between Depression and Neuroendocrine Metabolism

et al. 2021

View full text Add to dashboard Cite

Through the past decade of research, the correlation between depression and metabolic diseases has been noticed. More and more studies have confirmed that depression is comorbid with a variety of metabolic diseases, such as obesity, diabetes, metabolic syndrome and so on. Studies showed that the underlying mechanisms of both depression and metabolic diseases include chronic inflammatory state, which is significantly related to the severity. In addition, they also involve endocrine, immune systems. At present, the effects of clinical treatments of depression is limited. Therefore, exploring the co-disease mechanism of depression and metabolic diseases is helpful to find a new clinical therapeutic intervention strategy. Herein, focusing on the relationship between depression and metabolic diseases, this manuscript aims to provide an overview of the comorbidity of depression and metabolic.

show abstract

“…Disturbances in blood sugar regulation, insulin concentrations, and insulin resistance have been identified in depression [ 173 , 174 ]. Although the administration of antihyperglycaemic agents, including metformin and peroxisome proliferator-activated receptor-γ (PPARγ) receptor agonists, have yielded inconsistent findings in depression studies, insulin signalling has been shown to influence serotonergic transmission [ 173 , 174 ]. Based on a meta-analysis of four trials and 453 participants, it was concluded that curcumin supplementation may assist in improving insulin resistance and glycaemic control [ 175 ].…”

Section: Curcumin’s Potential Antidepressant Mechanisms Of Actionmentioning

confidence: 99%

Potential Role of Curcumin for the Treatment of Major Depressive Disorder

Lopresti

2022

CNS Drugs

View full text Add to dashboard Cite

Curcumin is the major biologically active polyphenolic constituent in the turmeric plant (Curcuma longa) that has been shown to have antioxidant, anti-inflammatory, neuroprotective, anticancer, antimicrobial, and cardioprotective effects. Interest in curcumin as a treatment for mental health conditions has increased and there is an expanding body of preclinical and clinical research examining its antidepressant and anxiolytic effects. In this narrative review, human trials investigating the effects of curcumin for the treatment of depression or depressive symptoms are summarised. Using findings from in vitro, animal, and human trials, possible biological mechanisms associated with the antidepressant effects of curcumin are also explored. To increase the understanding of curcumin for the treatment of depression, directions for future research are proposed. Key PointsEvidence from animal and human trials confirms curcumin is a promising treatment for depression.Curcumin has multiple biological actions that may account for its antidepressant effects.More research is required to increase the understanding of the antidepressant effects of curcumin.

show abstract

Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review

Cited by 22 publications

References 232 publications

Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives

Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives

Update on the Relationship Between Depression and Neuroendocrine Metabolism

Potential Role of Curcumin for the Treatment of Major Depressive Disorder

Contact Info

Product

Resources

About